Nmda antagonists as neurotherapeutic drugs, psychotogens, neurotoxins, and research tools for studying schizophrenia

Neuropsychopharmacology

Volumn 13, Issue 4, 1995, Pages 335-345

  Olney, John W ^a   Farber, Nuri B ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Addiction; Emergence reactions; NMDA antagonist neurotoxicity; Pain; Posterior cingulate and retrosplenial cortices; Psychosis; Schizophrenia

Indexed keywords

GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROTOXIN;

ANIMAL EXPERIMENT; BRAIN INJURY; CENTRAL NERVOUS SYSTEM; DOPAMINERGIC SYSTEM; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PSYCHOSIS; RAT; REVIEW; SCHIZOPHRENIA;

AGE FACTORS; ANIMALS; BRAIN; BRAIN DISEASES; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RATS; RECEPTORS, GLUTAMATE; SCHIZOPHRENIA;

EID: 0029592136     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1016/0893-133X(95)00079-S     Document Type: Review

References (77)

1. Backonja M, Arndt G, Gombar KA, Check B, Zimmermann M (1994): Response of chronic neuropathic pain syndromes to ketamine: A preliminary study. Pain 56:51-57
2. Balazs R, Hack N, Jorgensen OS (1988): Stimulation of the N-methyl-D-aspartate receptor has a trophic effect on differentiating cerebellar granule cells. Neurosci Lett 87:80-86
3. Benes FM, Davidson J, Bird FD (1986): Quantatative cytoar-chitectural studies of the cerebral cortex of schizophrenics. Arch Gen Psychiatry 43:31 35
4. Benes FM, McSparrenJ, San-Giovanm JP, Vincent SL (1991): Deficits in small interneurons in cingulate cortex of schizophrenic and schizoaffective patients. Arch Gen Psychiatry 48:996-1001
5. Bogerts B, Meertz E, Schonfeldt Bausch R (1985): Basal ganglia and limbic system pathology in schizophrenia: Amorphometric study of brain volume and shrinkage. Arch Gen Psychiatry 42:784-791
6. Bogerts B, Falkai P, Tutsch J (1986): Cell numbers in the pallidum and hippocampus of schizophrenics. In Shagass C. Josiassen RC, Bridger WH, Weiss KJ, Stoff D, Simpson GM (eds), Biological Psychiatry, vol 7, Amsterdam, Elsevier, pp 1178-1180
7. Bogerts B (1993): Recent advances in the neuropathology of schizophrenia. Schisophrenia Bull 19:431-445
8. Brown R, Colter N, Corsellis JAN, Crow TJ, Frith CD, Jagoe R, Johnstone EC, Marsh L (1986): Post-mortem evidence for structural brain changes in schizophrenia. Differences in brain weight, temporal horn area and parahippoam-pal gyrus width as compared with affective disorder. Arch Gen Psychiatry 43:36-42
9. Campochiaro P, Coyle JT (1978): Ontogenetic development of kainate neurotoxicity: Correlates with glutamatergic innervation. Proc Natl Acad Sci 75:2025-2029
10. Corso T, Neafsey EL, Collins M (1992): Ethanol-induced degeneration of dentate gyrus, entorhinal cortex and other olfactor related areas in rat: Effects of co-administration of MK-801, DNQX, or nimodipine. Soc Neurosci Abstr 18:540
11. Corso TD, Wozniak DF, Sesma MA, Olney JW (1994): Neuron necrotizing properties of phencyclidine. Soc Neurosci Abstr 20:1531
12. Davar G, Hama A, Deykin A, Vos B, Maciewicz R (1991): MK-801 blocks the development of thermal hyperalgesia in a rat model of experimental painful neuropathy. Brain Res 553:327-330
13. Deutsch SI, Mastropaolo J, Schwartz BL, Rosse RB, Morihisa JM (1989): A "glutamatergic hypothesis" of schizophrenia. Rationale for pharmacotherapy with glycine. Clin Neuropharmacol 12(1):1-13
14. Duval D, Roome N, Gauffeny C, Nowicki JP, Scatton B (1992): SL 82.0715, an NMDA antagonist acting at the polyamine site, does not induce neurotoxic effects on rat cortical neurons. Neurosci Lett 137:193-197
15. Ellison G, Switzer RC (1993): Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 5:17-20
16. Ellison G (1994): Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5:2688-2692
17. Falkai P, Bogerts B (1986): Cell loss in the hippocampus of schizophrenics. Psychiatr Neurol Sci 236:154-161
18. Falkai P, Bogerts B, Rozumek M (1988): Limbic pathology in schizophrenia: The entorhinal region—A morphometric study. Biol Psychiatry 24:515-521
19. Farber NB, Price MT, Labruyere J, Fuller TA, Olney JW (1992): Age dependency of NMDA antagonist neurotoxicity. Soc Neurosci Abstr 18:1148
20. Farber NB, Price MT, Labruyere J, Nemnich J, St Peter H, Wozniak DF, Olney JW (1993a): Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry 34:119-121
21. Farber NB, Price MT, Labruyere J, Nemnich J, St Peter H, Olney JW (1993b): Protection against NMDA antagonist neurotoxicity by clozapine and related analogs correlates with antipsychotic efficacy. Soc Neurosci Abstr 19:384
22. Farber NB, Foster J, Duhan NL, Olney JW (1995a): A2 adrenergic agonists prevent MK-801 neurotoxicity-Neuropsychopharmacology 12(4):347-349
23. Farber NB, Foster J, Olney JW (1995b): Clozapine and related analogs block NMDA antagonist neurotoxicity: Implications for schizophrenia. Schizophr Res 15(l, 2):57-58
24. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H, Olney JW (1995c): Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: Poten tial relevance to schizophrenia? Biol Psychiatry 37:(in press)
25. Fayen M, Goldman MB, Moulthrop MA, Luchins DJ (1988): Differential memory function with dopaminergic versus anticholinergic treatment of drug-induced extrapyrami-dal symptoms. Am J Psychiatry 145:483-486
26. Fisch RJ (1987): Trihexiphenidyl abuse: Therapeutic implied tions for negative symptoms of schizophrenia. Acta Psv-chiatr Scand 75:91-94
27. Fix AS, Horn JW, Wightman KA, Johnson CA, Long GC Storts RW, Farber NB, Wozniak DF, Olney JW (1993): Neuronal vacuolization and necrosis induced by the non-competitibve N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (Dizocilipine Maleate): A light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol 123:204-215
28. Grotta J (1994): Safety and tolerability of the glutamate antagonist CGS 19755 in acute stroke patients. Stroke 25:255
29. Gue M, Junien JL, Del Rion C and Bueno L (1992). Neuropeptide Y and Sigma ligand (JO 1784) suppress stress-induced colonic motor distrubances in rats through sigma and cholecystokinin receptors. J Pharm ExpTher 261:850-855
30. Hargreaves RJ, Rigby M, Smith D, Hill RG, Iversen LL (1993a): Competitive as well as uncompetitive NMDA receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem Res 19:1263-1269
31. Hargreaves RJ, Rigby M, Smith D, Hill RG (1993b): Lack of effect of L-687, 414[(+)-cis-4-methyl-HA-966, an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology Br J Pharmacol 110:36-42
32. Herrling PL (1994): D-CPPene (SDZ EAA 494), A competitive NMDA antagonist: Results from animal models and first results in humans. Neuropsychopharmacologv 10:591S
33. Horvath Z, Buzsaki G (1993): MK-801-induced neuronal dam -age in normal rats. Soc Neurosci Abstr 19:354
34. Ikonomidou C, Price MT, Mosinger JL, Frierdich G, Labruvere J, Shahid Salles K, Olney JW (1989a): Hypbaric-ischemic conditions produce glutamate-like cytopathologv in infant rat brain. J Neurosci 9:1693-1700
35. Ikonomidou C, Mosinger JL, Shahid Salles K, Lubryere I Olney JW (1989b): Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity. J Neurosci 9:2809-2818
36. Ikonomidou C, Qin YO, Labruyere J, Olney JW (1994): Trauma causes glutamatetype cytopathologv in infant rat brain Soc Neurosci Abstr 20:1677
37. Jakob H, Beckman H (1986): Prenatal developmental distur bances in the limbic allocortex in schizophrenics. J Neural Transmiss 65:303-326
38. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Linden-mayer JP (1994): Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 151:1234-1236
39. Jeste D, Lohr JB (1989): Hippocampal pathologic findings in schizophrenia. Arch Gen Psychiatry 46:1019-1024
40. Kornhuber J, Kornhuber ME (1986): Presynaptic dopaminergic modulation of cortical input to the striatum. Life Sci 39:699-674
41. Kovelman JA, Scheibel AB (1984): A neurohistological correlate of schizophrenia. Biol Psychiatry 191:1601-1621
42. Kristensen JD, Svensson B, Gordh T (1992): The NMDA-receptor antagonist CPP abolishes neurogenic "wind-up pain" after intrathecal administration in humans. Pain 51:249-253
43. Lodge D, Aram JA, Church J, Davies SN, Martin D, O'Shaughnessy CT, Zeman S (1987): Excitatory amino acids and phencyclidine-like drugs. In Hicks TP, Lodge D, McLennan H (eds), Excitatory Amino Acid Transmission. New York, Alan R. Liss, pp 83-90
44. Lodge D, Anis NA (1982): Effects of phencyclidine on excitatory amino acid activation of spinal interneurons in the cat. Eur J Pharmacol 77:203-204
45. McDonald JW, Silverstein FS, Johnston MV (1987): MK-801 protects the neonatal brain from hypoxic-ischemic damage. Eur J Pharmacol 140:359-361
46. McDonald JW, Silverstein FS, Johnston MV (1988): Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system. Brain Res 459: 200-203
47. McDonald JW, Trescher WH, Johnston MV (1991): The pattern and degree of selective vulnerability to excitotoxic brain injury is dependent upon developmental age. Fidia Res Fnd Sym Series 5:609-614
48. Marshall BE, Longnecker DE (1990): General anesthetics. In Goodman LS, Gilman A, Rail TW, Nies AS, Taylor P (eds), The Pharmacologic Basis of Therapeutics. New York, Pergamon, pp 285-310
49. Maura G, Giardi A, Raiteri M (1988): Release-regulating D2 dopamine receptors are located on striatal glutamater-gic nerve terminals. J Pharmacol Exp Ther 247:680-684
50. Maura G, Carbone R, Raiteri M (1989): Aspartate-releasing nerve terminals in rat striatum possess D2 dopamine receptors mediating inhibition of release. J Pharmacol Exp Ther 251:1142-1146
51. Maura G, Barzizza A, Lottero P, Raiteri M (1990): The excitatory amino acid-releasing nerve terminals in rat striatum possess D2 dopamine receptors mediating inhibition of release. Neurochem Inter 16:53
52. Monnet FP, Debonnel G, Junien JL, De Montigny C (1990). N-methyl-D-aspartate-induced neuronal activation is selectively modulated by sigma receptors. Eur J. Pharmacol 179:441-445
53. Monnet FP, Debonnel G, and De Montigny C (1992). In vivo electrophysiologic evidence for a selective modulation on N-methyl-D-aspartate-induced neuronal activation in rat CA3 dorsal hippocampus by sigma ligands. J Pharmacol Exp Ther 261:123-130
54. Monyer HR, Burnashev N, Laurie DJ, Sakmann B, Seeburg PH (1994): Developmental and regional expression in the rat brain and functional properties of four NMD A receptors. Neuron 12:529-540
55. Olney JW (1988): Endogenous excitotoxins and neuropatho-logical disorders. In Lodge D (ed), Excitatory Amino Acids in Health and Disease. England, John Wiley and Sons, pp 337-351
56. Olney JW (1989): Excitatory amino acids and neuropsychiatric disorders. Biol Psychiatry 26:505-525
57. Olney JW, Farber NB (1994): Efficacy of clozapine compared to other antipsychotics in preventing NMDA antagonist neurotoxicity. J Clin Psychiatry 55:9 (supplement 8) 43-46
58. Olney JW, Farber NB(1995): Glutamate receptor dysfunction and schizophrenia. Arch Gen Psvchiatrv (in press)
59. Olney JW, Ikonomidou C, Mosinger JL, Frierdich G (1989a) MK-801 prevents hypobaric-ishemic neuronal degener ation in infant rat brain. J Neurosci 9:1701-1704
60. Olney JW, LabruyereJ, Price MT (1989b): Pathologic changes induced in cerebrocortical neurons by phencvclidine and related drugs. Science 244:1360-1362
61. Olney JW, Labruyere J, Wang G, Sesma MA, Wozniak DF. Price MT (1991): NMDA antagonist neurotoxicity: Mechanism and Protection. Science 254:1515-1518
62. Olney JW, Sesma MA, Wozniak DF (1993): Glutamatergic. cholinergic, and GABAergic systems m posterior cingulate cortex: Interactions and possible mechanism of limbic system disease. In Vogt BA, Gabriel M (eds), Neurobiology of Cingulate Cortex and Limbic Thalamus Boston, Birkhauser, pp 357-380
63. Pearce IA, Cambray-Deakin MA, Burgovne RD (1987): Glutamate acting on NMDA receptors stimulates neurite outgrowth from cerebellar granule cells. FEBS Lett 223 143-147
64. Price MT, Farber NB, Labruyere L Foster J, Olney JW (1994) Tracing the circuitry that mediates NMDA antagonist neurotoxicity. Soc Neurosci Abstr 20:1532
65. Puke MJC, Wiesenfeld-Hallin Z (1993): The differential effects of morphine and the a;-adrenoceptor agonists clonidine and dexmedetomidine on the prevention and treatment of experimental neuropathic pam. Anesth Analg 77 104-109
66. Riviere PJM, Pascaud X. lumen I I Porreca F (1990). Neuropeptide Y and JO 1784, a -.electn e sigma ligand, alterintestinalion transport through a common, haloperidol-sensitive site. Eur J Pharmacol 187:557-559
67. Rowlands GC, Roberts PJ (1980): Activation of domapine receptors inhibits calcium-dependent glutamate release from cortico-striatal terminals in vitro. Eur J Pharmacol 62:241-247
68. Schwarcz R, Creese 1, Coyle JT, Snyder SH (1978): Dopamine receptors localized on cerebral cortical afferents to rat corpus striatum. Nature 271:766-768
69. Sharp FR, Butman M, Koistinaho J, Aardalen K, Nakki R, Massa SM, Swanson R, Sagar SM (1994): Phencyclidine induction of hsp70 stress gene in injured pyramidal neurons is mediated via multiple receptors and voltage gated calcium channels. Neuroscience 62(4): 1079-1092
70. shenton ME, Kikinis R, Jolesz FA, Poliak SD, LeMay M, Wible CG, Hokama H, Martin J, Metcalf D, Coleman M, McCarley RW (1992): Abnormalities of the left temporal lobe and thought disorder in schizophrenia: A quantitative magnetic resonance imaging study. N Engl J Med 327:604-612
71. Fandon R, Greden JF, Silk KR (1988): Treatment of negative schizophrenic symptoms with trihexiphenidyl. J Clin Psy-chopharmacol 8:212-215
72. Fandon R, Greden JF (1989): Cholinergic hyperactivity and negative schizophrenic symptoms. Arch Gen Psychiatry 46:745-753
73. Fandon R, Shipley JE, Greden JF, Mann NA, Eisner WH, Goodson J (1991): Muscarinic cholinergic hyperactivity in schizophrenia. Relationship to positive and negative symptoms. Schizophr Res 4:23-30
74. Walker FA, Seig JA (1973): Phencyclidine an environmental teratogen. Mutat Res 21:348-349
75. Wells BG, Marken PA, Richman LA, Brown CS, Hamann G, Grimmig I (1989): Characterizing anticholinergic abuse in community mental health. J Clin Pharmacol9:431-435
76. Wozniak DF, McEwen M, Sesma MA, Olney JW, Fix AS (1993): MK-801 induces extensive neuronal necrosis in posterior cingulate-'retrosplenial cortices. Soc Neurosci Abstr 19:1770
77. Zeigler D, Lynch SA, Muir J, Benjamin J, Max MB (1992): Transdermal clonidine versus placebo in painful diabetic neuropathy. Pain 48:403-408